Post by Spyridon Tsakas

Tsakas Fragility Radar | Top 20 Global Pharmaceutical Companies by 2025 Revenue Revenue creates scale. Resilience sustains leadership. The world’s largest pharmaceutical companies generated more than $1 trillion in combined revenue during 2025, but every one of them faces the same question: How resilient is your business when disruption becomes the norm? Top 20 Global Pharmaceutical Companies by 2025 Revenue (USD Billions) 1. Johnson & Johnson — $94.2B 2. Roche — $74.0B 3. Eli Lilly — $65.2B 4. Merck & Co. — $65.0B 5. Pfizer — $62.6B 6. AbbVie — $61.2B 7. AstraZeneca — $58.7B 8. Novartis — $54.5B 9. Bristol Myers Squibb — $48.2B 10. Sanofi — $46.0B 11. Novo Nordisk — $44.8B 12. Abbott Laboratories — $44.3B 13. GSK — $41.1B 14. Shanghai Pharmaceuticals — $38.7B 15. Amgen — $36.8B 16. Gilead Sciences — $29.4B 17. Boehringer Ingelheim — $29.4B 18. Takeda — $29.3B 19. Siemens Healthineers — $23.2B 20. Merck KGaA — $23.2B Revenue is a lagging indicator. Fragility is a leading indicator. The companies that identify systemic vulnerabilities before they become crises will be the ones defining the next decade of pharmaceutical leadership. #TsakasFragilityRadar #JohnsonAndJohnson #Roche #EliLilly #Merck #Pfizer #AbbVie #AstraZeneca #Novartis #BristolMyersSquibb #Sanofi #NovoNordisk #Abbott #GSK #ShanghaiPharmaceuticals #Amgen #Gilead #BoehringerIngelheim #Takeda #SiemensHealthineers #MerckKGaA